-
公开(公告)号：US20190105400A1
公开(公告)日：2019-04-11
申请号：US15418180
申请日：2017-01-27
申请人： Ulrich Hersel , Harald Rau , Torben Lessmann , Nicola Bisek , Guillaume Maitro , Kennett Sprogoe , Thomas Wegge , Oliver Keil , Joachim Zettler
发明人： Ulrich Hersel , Harald Rau , Torben Lessmann , Nicola Bisek , Guillaume Maitro , Kennett Sprogoe , Thomas Wegge , Oliver Keil , Joachim Zettler
摘要： The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).
-
公开(公告)号：US09561287B2
公开(公告)日：2017-02-07
申请号：US14238437
申请日：2012-08-10
申请人： Ulrich Hersel , Harald Rau , Torben Lessmann , Nicola Bisek , Guillaume Maitro , Kennett Sprogøe , Thomas Wegge , Oliver Keil , Joachim Zettler
发明人： Ulrich Hersel , Harald Rau , Torben Lessmann , Nicola Bisek , Guillaume Maitro , Kennett Sprogøe , Thomas Wegge , Oliver Keil , Joachim Zettler
IPC分类号： A61K47/48
CPC分类号： A61K47/48253 , A61K47/60 , A61K47/641 , A61K47/645
摘要： The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).
摘要翻译： 本发明涉及包含共价曲前列腺素载体缀合物的前药或其药学上可接受的盐以及包含所述化合物的药物组合物。 这些化合物可以用作药物，特别是可以通过曲前列素治疗的疾病或病症，例如肺动脉高压（PAH）。
-
公开(公告)号：US20140296150A1
公开(公告)日：2014-10-02
申请号：US14238437
申请日：2012-08-10
申请人： Ulrich Hersel , Harald Rau , Torben Lessmann , Nicola Bisek , Guillaume Maitro , Kennett Sprogøe , Thomas Wegge , Oliver Keil , Joachim Zettler
发明人： Ulrich Hersel , Harald Rau , Torben Lessmann , Nicola Bisek , Guillaume Maitro , Kennett Sprogøe , Thomas Wegge , Oliver Keil , Joachim Zettler
IPC分类号： A61K47/48
CPC分类号： A61K47/48253 , A61K47/60 , A61K47/641 , A61K47/645
摘要： The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).
摘要翻译： 本发明涉及包含共价曲前列腺素载体缀合物的前药或其药学上可接受的盐以及包含所述化合物的药物组合物。 这些化合物可以用作药物，特别是可以通过曲前列素治疗的疾病或病症，例如肺动脉高压（PAH）。
-
公开(公告)号：US10729778B2
公开(公告)日：2020-08-04
申请号：US15418180
申请日：2017-01-27
申请人： Ulrich Hersel , Harald Rau , Torben Lessmann , Nicola Bisek , Guillaume Maitro , Kennett Sprogøe , Thomas Wegge , Oliver Keil , Joachim Zettler
发明人： Ulrich Hersel , Harald Rau , Torben Lessmann , Nicola Bisek , Guillaume Maitro , Kennett Sprogøe , Thomas Wegge , Oliver Keil , Joachim Zettler
摘要： Prodrugs or a pharmaceutically acceptable salt thereof which comprise a covalent treprostinil carrier conjugate, as well as their pharmaceutical composition, may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).
-
公开(公告)号：US20120183616A1
公开(公告)日：2012-07-19
申请号：US13387959
申请日：2010-07-30
申请人： Kennett Sprogoe , Felix Cleemann , Ulrich Hersel , Silvia Kaden-Vagt , Torben Lessmann , Harald Rau , Thomas Wegge
发明人： Kennett Sprogoe , Felix Cleemann , Ulrich Hersel , Silvia Kaden-Vagt , Torben Lessmann , Harald Rau , Thomas Wegge
CPC分类号： A61K9/06 , A61K9/0019 , A61K9/19 , A61K38/26 , A61K38/28 , A61K45/06 , A61K47/50 , A61K47/60 , A61K47/69 , Y10T428/13 , A61K2300/00
摘要： The present invention relates to a pharmaceutical composition comprising an insulin compound in a concentration that is sufficient to maintain a therapeutically effective level of the insulin compound in blood plasma for at least 3 days characterized by having a pharmacokinetic profile in vivo with substantially no burst of the insulin compound. The present invention further relates to the use of an insulin compound for preparing said pharmaceutical composition as well as a kit of parts comprising said pharmaceutical composition.
摘要翻译： 本发明涉及包含胰岛素化合物的药物组合物，其浓度足以将血浆中的胰岛素化合物的治疗有效水平维持在血浆中至少3天，其特征在于在体内具有药代动力学特征，基本上没有 胰岛素复合物。 本发明还涉及胰岛素化合物用于制备所述药物组合物的用途以及包含所述药物组合物的试剂盒。
-
公开(公告)号：US09265723B2
公开(公告)日：2016-02-23
申请号：US13387959
申请日：2010-07-30
申请人： Kennett Sprogoe , Felix Cleemann , Ulrich Hersel , Silvia Kaden-Vagt , Torben Lessmann , Harald Rau , Thomas Wegge
发明人： Kennett Sprogoe , Felix Cleemann , Ulrich Hersel , Silvia Kaden-Vagt , Torben Lessmann , Harald Rau , Thomas Wegge
CPC分类号： A61K9/06 , A61K9/0019 , A61K9/19 , A61K38/26 , A61K38/28 , A61K45/06 , A61K47/50 , A61K47/60 , A61K47/69 , Y10T428/13 , A61K2300/00
摘要： The present invention relates to a pharmaceutical composition comprising an insulin compound in a concentration that is sufficient to maintain a therapeutically effective level of the insulin compound in blood plasma for at least 3 days characterized by having a pharmacokinetic profile in vivo with substantially no burst of the insulin compound. The present invention further relates to the use of an insulin compound for preparing said pharmaceutical composition as well as a kit of parts comprising said pharmaceutical composition.
摘要翻译： 本发明涉及包含胰岛素化合物的药物组合物，其浓度足以将血浆中的胰岛素化合物的治疗有效水平维持在血浆中至少3天，其特征在于在体内具有药代动力学特征，基本上没有 胰岛素复合物。 本发明还涉及胰岛素化合物用于制备所述药物组合物的用途以及包含所述药物组合物的试剂盒。
-
公开(公告)号：US20140303245A1
公开(公告)日：2014-10-09
申请号：US14238147
申请日：2012-08-10
申请人： Kennett Sprogøe , Harald Rau , Ulrich Hersel , Thomas Wegge , Oliver Keil , Joachim Zettler
发明人： Kennett Sprogøe , Harald Rau , Ulrich Hersel , Thomas Wegge , Oliver Keil , Joachim Zettler
IPC分类号： A61K31/5585 , A61K47/48
CPC分类号： A61K31/5585 , A61K31/557 , A61K47/60
摘要： The present invention relates to sustained release compositions of prostacyclin, as well as uses thereof, in particular for the prevention and/or treatment of pulmonary arterial hypertension.
摘要翻译： 本发明涉及前列环素的缓释组合物及其用途，特别是用于预防和/或治疗肺动脉高血压。
-
公开(公告)号：US09872864B2
公开(公告)日：2018-01-23
申请号：US14238147
申请日：2012-08-10
申请人： Kennett Sprogøe , Harald Rau , Ulrich Hersel , Thomas Wegge , Oliver Keil , Joachim Zettler
发明人： Kennett Sprogøe , Harald Rau , Ulrich Hersel , Thomas Wegge , Oliver Keil , Joachim Zettler
IPC分类号： A61K31/215 , A61K31/5585 , A61K31/557 , A61K47/60
CPC分类号： A61K31/5585 , A61K31/557 , A61K47/60
摘要： The present invention relates to sustained release compositions of prostacyclin, as well as uses thereof, in particular for the prevention and/or treatment of pulmonary arterial hypertension.
-
公开(公告)号：US20110112021A1
公开(公告)日：2011-05-12
申请号：US12990101
申请日：2009-04-29
申请人： Harald Rau , Susanne Kindermann , Torben Lebmann , Grethe Norskov Rasmussen , Ulrich Hersel , Thomas Wegge , Kennett Sprogoe
发明人： Harald Rau , Susanne Kindermann , Torben Lebmann , Grethe Norskov Rasmussen , Ulrich Hersel , Thomas Wegge , Kennett Sprogoe
摘要： A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
摘要翻译： 通过连接包含聚乙二醇的瞬时接头制备的化学修饰的人生长激素（rhGH）。 化学修饰的蛋白质可能具有比未修饰的rhGH更持久的rhGH活性，能够减少剂量和调度机会，并且修饰的rhGH可能不引起脂肪萎缩。 还包括用于治疗和/或预防使用生长激素有益的疾病或病症的方法。
-
公开(公告)号：US09272048B2
公开(公告)日：2016-03-01
申请号：US12990101
申请日：2009-04-29
申请人： Harald Rau , Susanne Kinderman , Torben Lebmann , Grethe Norskov Rasmussen , Ulrich Hersel , Thomas Wegge , Kennett Sprogoe
发明人： Harald Rau , Susanne Kinderman , Torben Lebmann , Grethe Norskov Rasmussen , Ulrich Hersel , Thomas Wegge , Kennett Sprogoe
摘要： A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
摘要翻译： 通过连接包含聚乙二醇的瞬时接头制备的化学修饰的人生长激素（rhGH）。 化学修饰的蛋白质可能具有比未修饰的rhGH更持久的rhGH活性，能够减少剂量和调度机会，并且修饰的rhGH可能不引起脂肪萎缩。 还包括用于治疗和/或预防使用生长激素有益的疾病或病症的方法。
-
-
-
-
-
-
-
-
-
搜索结果
65 条记录 (耗时 0.043 秒)
